When a newborn struggles to take their first breath, or an adult with ARDS fights against stiff, fluid-filled lungs, the missing piece is often the same: surfactant. This natural substance, a complex mix of lipids and proteins, is what keeps our alveoli from collapsing. Without enough of it, breathing becomes a battle. For decades, surfactant therapy was reserved almost exclusively for premature infants with neonatal respiratory distress syndrome (NRDS). But the landscape has changed. In 2026, clinicians are using surfactant therapy for a wider range of conditions, including acute respiratory distress syndrome (ARDS) in adults, meconium aspiration syndrome, and even pneumonia. This guide walks through the current protocols, practical steps, and key considerations for using surfactant therapy effectively across different patient populations.

Understanding the Role of Surfactant in Respiratory Distress

Surfactant reduces surface tension inside the alveoli. This prevents collapse at the end of expiration and keeps the lungs compliant. When surfactant is deficient or inactivated, as happens in NRDS or ARDS, the work of breathing skyrockets. Gas exchange suffers. The patient tires out.

In neonates, the problem is developmental. Their type II pneumocytes have not yet produced enough surfactant. In adults, the problem is more complex. Inflammatory exudates, plasma proteins, and cellular debris from conditions like sepsis, aspiration, or trauma directly inactivate existing surfactant. The result is the same: widespread atelectasis, shunt physiology, and refractory hypoxemia.

Key Differences Between Neonatal and Adult Protocols

While the goal is the same, the approach differs significantly between neonates and adults. Here is a breakdown of the main differences.

Parameter	Neonatal NRDS	Adult ARDS
Primary cause	Surfactant deficiency	Surfactant inactivation
Typical timing	Within 30 minutes of birth	Within 24 to 48 hours of intubation
Delivery method	Endotracheal instillation via catheter	Bronchoscopic instillation or nebulized delivery
Dose	100 to 200 mg phospholipid/kg	50 to 100 mg phospholipid/kg (higher total volume)
Repeat doses	Up to 3 to 4 doses	Often 1 to 2 doses, based on FRC and compliance
Common formulation	Animal-derived (beractant, calfactant)	Synthetic (lucinactant) or animal-derived
Ventilation strategy	Gentle, minimal handling	Lung protective, low tidal volume, high PEEP

A Practical Step-by-Step Protocol for Surfactant Administration

Applying surfactant therapy requires more than just drawing up a vial. The process must be deliberate to avoid complications like airway obstruction, reflux, or transient hypoxia.

1. Assess readiness. Confirm the patient meets criteria. For neonates, this means an oxygen requirement above 30% to 40% and a clear chest radiograph showing NRDS. For adults, use the ARDS Berlin definition or a clinical diagnosis of refractory hypoxia with a P/F ratio below 200. Ensure the patient is stable on the ventilator.

2. Choose the right product and dose. Animal-derived surfactants like beractant and calfactant are standard for neonates. Synthetic options like lucinactant offer consistency and are increasingly used in adults. Calculate the dose based on ideal body weight, not actual weight, to avoid overloading the lungs.

3. Prepare the delivery system. For neonates, use a 5 French feeding tube or a dedicated surfactant catheter. For adults, a flexible bronchoscope or a specialized nebulizer works best. Pre-warm the surfactant to room temperature. Do not shake the vial vigorously, as this can create foam.

4. Position the patient. In neonates, place the infant supine with the head midline. In adults, a slight reverse Trendelenburg position helps distribute the surfactant more evenly to dependent lung zones.

5. Administer in aliquots. Split the total dose into 3 to 5 smaller aliquots. Deliver each aliquot over 10 to 15 seconds. Rotate the patient’s head or the bronchoscope tip between aliquots to improve distribution. Pause for 30 to 60 seconds between each aliquot to allow the surfactant to spread.

6. Reassess and adjust ventilation. After administration, watch for a drop in FiO2 requirement or an improvement in compliance. Increase PEEP slightly to keep recruited alveoli open. Avoid aggressive suctioning for at least 2 to 4 hours after the procedure.

Common Mistakes and How to Avoid Them

Even experienced clinicians can run into trouble with surfactant therapy. Here are the most frequent pitfalls and how to steer clear of them.

• Delaying the first dose. In neonates, every minute counts. Waiting too long can lead to barotrauma from aggressive ventilation. Aim for administration within the first 30 minutes of life if the infant is intubated.
• Using the wrong delivery method for adults. Instilling surfactant through a standard endotracheal tube without a catheter or bronchoscope leads to pooling in the right mainstem bronchus. This causes unilateral distribution and can worsen shunt physiology.
• Forgetting to pre-oxygenate. Before each aliquot, increase the FiO2 to 100% for 30 seconds. This prevents desaturation during the brief pause in ventilation.
• Over-titrating PEEP. More is not always better. After surfactant, the lung is more recruitable. Too much PEEP can overdistend compliant alveoli and cause hypotension. Use a PEEP decrement trial to find the optimal setting.
• Ignoring the patient’s hemodynamics. Surfactant administration can transiently drop cardiac output due to increased intrathoracic pressure. Watch the arterial line closely, especially in adults with pre-existing right heart strain.

Expert advice: “If you see a sudden drop in SpO2 during administration, pause immediately. Check the ETT for reflux. In neonates, a small amount of reflux is normal. In adults, it often means you are instilling too fast or using too much volume per aliquot. Slow down and reposition the scope.” — Dr. Maria Chen, Pediatric Pulmonologist

When Surfactant Therapy Falls Short

Surfactant therapy is not a magic bullet. It works best when the underlying lung injury is reversible and the patient has some capacity for endogenous surfactant production. In severe ARDS with extensive fibrosis or in neonates with profound lung hypoplasia, the benefit may be limited.

Consider these factors before starting:

• Duration of illness. Surfactant given after 5 to 7 days of ARDS often shows diminishing returns. By that point, the inflammatory cascade is well established and structural damage may be irreversible.
• Type of lung injury. Direct lung injury from pneumonia or aspiration responds better to surfactant than indirect injury from sepsis or pancreatitis.
• Availability of rescue therapies. Surfactant therapy pairs well with optimizing mechanical ventilation strategies for ARDS patients. It also complements emerging technologies transforming critical care for respiratory failure. Using these together often yields better outcomes than surfactant alone.

How to Select the Right Surfactant Formulation

The choice between animal-derived and synthetic surfactant depends on the patient population and clinical scenario.

Animal-derived surfactants
– Pros: Contain natural SP-B and SP-C proteins. Highly effective for NRDS.
– Cons: Risk of batch variability. Animal protein can trigger immune reactions in some adults.
– Best for: Neonates, especially under 32 weeks gestation.

Synthetic surfactants
– Pros: Consistent composition. No animal-derived components. Some newer formulations include synthetic SP-B and SP-C analogs.
– Cons: Historically less effective than animal-derived options, though newer generations have closed the gap.
– Best for: Adults with ARDS, patients with religious or cultural restrictions on animal products, and repeat dosing scenarios.

Recombinant surfactants
– Pros: Contain human-sequence proteins. Low immunogenicity.
– Cons: Expensive. Limited availability in 2026.
– Best for: Clinical trials and patients with known sensitivity to animal proteins.

Monitoring Response After Administration

After giving surfactant, do not just walk away. Track these metrics over the next 4 to 6 hours.

• Oxygenation index (FiO2 x MAP / SpO2). A drop of 20% or more indicates good response.
• Static compliance. Should improve by 15% to 30% within the first hour.
• Chest radiograph. Look for more uniform aeration and less atelectasis in dependent regions.
• Ventilator waveforms. A smoother pressure-volume loop suggests better alveolar recruitment.

If the patient does not respond within 2 hours, reassess the delivery method. It is possible the surfactant pooled in one area or that the dose was too low. Consider a second dose with a different positioning strategy.

The Future of Surfactant Therapy in 2026 and Beyond

Research is pushing surfactant therapy into new territory. Nebulized delivery systems are improving particle deposition in adults, reducing the need for bronchoscopy. New synthetic surfactants with added anti-inflammatory peptides are being tested. Some teams are even working on surfactant replacement combined with how exosome therapy is reshaping treatment for acute respiratory distress syndrome in 2026. The goal is to not only replace what is missing but also calm the inflammatory storm that inactivates it.

Putting Evidence into Practice

Surfactant therapy is a powerful tool when used correctly. The key is to match the approach to the patient. For a 28-week preemie, act fast, use an animal-derived product, and keep the ventilation gentle. For a 45-year-old with sepsis-related ARDS, take the time to position the bronchoscope, use a synthetic surfactant, and pair it with a lung protective ventilation strategy. In both cases, the principles are the same: deliver the right surfactant, to the right place, at the right time.

Keep your skills current. Review the latest protocols, practice with simulators, and discuss cases with your respiratory therapy team. Every patient who struggles to oxygenate deserves a chance at this therapy done well.